Biologic treatments for rheumatoid arthritis
Biologic disease ‐modifying antirheumatic drugs (bDMARDs) have made a significant difference to the lives of people with rheumatoid arthritis (RA), in particular those who do not respond to conventional drugs. In this article the authors review the place in therapy of bDMARDs for RA and consider a range of factors that could contribute to further improvements to patient otucomes.
Publication date: Available online 4 June 2020Source: The Egyptian RheumatologistAuthor(s): Eman A.M. Alkady, Zahraa I. Selim, Sohair K. Sayed, Hosam A. Yousef, Sara Farrag, Eman H. El-Hakeim
Abstract Objective: Autoimmune conditions tend to cluster in subjects with Addison's disease (AD) and probably also among their relatives. The aim of the study was to estimate the frequency of the endocrine gland-specific autoantibodies in first-degree relatives of patients with AD. Methods: Autoantibodies were investigated in 113 family members using RIA and ELISA assays. The control group comprised 143 age-matched volunteers. Results: Autoimmune diseases were diagnosed in 38.1% relatives. Hashimoto's thyroiditis was found in 20.3%, Graves' disease in 8.0%, vitiligo and type 1 diabetes in 3.5%, whereas ...
Human neutrophil elastase (HNE) is a major cause of the destruction of tissues in cases of several different chronic andinflammatory diseases. Overexpression of the elastase enzyme plays a significant role in the pathogenesis of various diseases including chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, rheumatoid arthritis, the rare disease cyclic hematopoiesis (or cyclic neutropenia), infections, sepsis, cystic fibrosis, myocardial ischemia/reperfusion injury and asthma, inflammation, and atherosclerosis. Human neutrophil elastase is secreted by human neutrophils due to different stimuli...
ConclusionAssessing only the availability of TNF alpha inhibitors on the national list of reimbursed medicines provides limited information about real-world patient access to these medicines. Revealing hidden access barriers may contribute to initiate policy actions which could reduce inequity in patient access.
ConclusionACPA and anti ‐modified protein autoantibodies (AMPA) represent overlapping facets of RA autoimmunity and bind to a wide variety of modified proteins, well beyond “historical” RA autoantigens. So far, KAc‐reactivity was only detected in context of anti‐Carb and anti‐Cit, postulating autoreactivity hie rarchies. Future investigations of ACPA fine‐specificities and functionality should take the consensus Cit/Carb/KAc‐motifs and multi‐reactivity into consideration.
A new study from the University of Michigan found that tocilizumab, a rheumatoid arthritis drug, reduced the liklihood of death for coronavirus patients on ventilators by 45%.
CONCLUSION: The MAP-Hand showed satisfactory construct validity and could differentiate between people with CMC1 OA and those with rheumatoid arthritis on item levels. PMID: 32490534 [PubMed - as supplied by publisher]
Condition: Rheumatoid Arthritis Intervention: Sponsor: Assiut University Not yet recruiting
Conditions: Rheumatoid Arthritis; Serum Albumin Low Intervention: Procedure: Blood and serum samples Sponsor: Assiut University Recruiting
Condition: Rheumatoid Arthritis Interventions: Drug: PF-06650833; Drug: PF-06651600; Drug: Tofacitinib Sponsor: Pfizer Not yet recruiting